News
Fact checked by Nick Blackmer I was first told that I was at higher risk for fatty liver disease in 2005. I had never heard ...
On a quest to expand the eligible patient pool for its fast-growing liver disease drug Rezdiffra, Madrigal Pharmaceuticals ...
7h
MyChesCo on MSNMadrigal Pharmaceuticals Reports Promising Two-Year Data for Rezdiffra in MASH CirrhosisCONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced two-year results from the open-label arm of ...
1d
Health on MSNRoad to Diagnosis: My Doctors' Focus on My Weight Delayed My MASH Diagnosis for YearsAroosha Sarrafi tells Health her story of getting diagnosed with metabolic dysfunction-associated steatohepatitis (MASH), a ...
Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...
GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening steatohepatitis.
A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by a common condition.
10d
Everyday Health on MSNWegovy May Halt and Even Reverse Severe Liver DiseaseA late-stage clinical study showed that this weight loss drug helped 2 out of 3 people with the life-threatening liver ...
The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...
California biotech NGM Bio is slimming down as the company pivots focus, shedding around 75% of staff, pausing development of ...
AMSTERDAM — A once daily, 50 mg dose of efruxifermin reduced fibrosis at 96 weeks in patients with compensated cirrhosis due ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results